GGHC
XENE icon

Gilder Gagnon Howe & Co’s Xenon Pharmaceuticals XENE Stock Holding History

Gilder Gagnon Howe & Co’s Portfolio XENE Stock Details XENE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-15,092
Closed -$650K – 282
2024
Q1 		$650K Buy
+15,092
New +$694K 0.01% 231

Other funds holding XENE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Gilder Gagnon Howe & Co's XENE Position: Q2 2024 in Review

Gilder Gagnon Howe & Co sold out of Xenon Pharmaceuticals (XENE) in Q2 2024, closing a stake of 15,092 shares — an estimated $650K sold.

Gilder Gagnon Howe & Co first reported a position in XENE in Q1 2024 and held it in 1 quarter. The position peaked at $650K in Q1 2024. 213 funds tracked by Wall St. Rank hold XENE as of Q2 2024.

  • Gilder Gagnon Howe & Co reported no remaining Xenon Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
  • Gilder Gagnon Howe & Co sold 15,092 Xenon Pharmaceuticals shares in Q2 2024, an estimated $650K.
  • Gilder Gagnon Howe & Co first reported a position in Xenon Pharmaceuticals in Q1 2024 and held it in 1 quarter.
  • Gilder Gagnon Howe & Co's Xenon Pharmaceuticals position peaked at $650K in Q1 2024.
  • 213 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q2 2024.

Based on Gilder Gagnon Howe & Co's 13F filing for Q2 2024, filed 14 Aug 2024.